IL33 and breast cancer: In mouse model of breast cancer, simultaneous blockade of both the IL-33/ST2 and PD-1/PD-L1 signalling pathways significantly delayed palpable tumour appearance (ST2–/– + antiPD1 vs. WT= 15th vs. 10th day) and slowed tumour growth [108].